Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.47 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.46 |
| ▸ | GRPR | P30550 | 1/20 | 0.46 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 1/20 | 0.45 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29455880 | 0.96 | TFPI (0.53) | TFPIRXFP1IL23R | |
| SCHEMBL31182934 | 0.95 | RXFP1 (0.58) | TFPIRXFP1VIPR2VIPR1ECE1 | |
| SCHEMBL30844336 | 0.93 | RXFP1 (0.54) | TFPIRXFP1IL23RVIPR2VIPR1 | |
| SCHEMBL28081230 | 0.91 | TFPI (0.54) | TFPIRXFP1VIPR2VIPR1ECE1 | |
| SCHEMBL29435830 | 0.91 | TFPI (0.56) | TFPIRXFP1VIPR2 | |
| SCHEMBL28518994 | 0.90 | TFPI (0.54) | TFPIRXFP1VIPR2VIPR1 | |
| SCHEMBL28081205 | 0.90 | TFPI (0.54) | TFPIRXFP1VIPR2VIPR1 | |
| SCHEMBL28081112 | 0.90 | TFPI (0.54) | TFPIRXFP1VIPR2VIPR1 | |
| SCHEMBL30140825 | 0.89 | TFPI (0.52) | TFPIRXFP1VIPR2VIPR1 | |
| SCHEMBL29736280 | 0.89 | IL23R (0.46) | TFPIRXFP1IL23RVIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115066254-A | Human anti-inflammatory peptides for inhalation treatment of inflammatory lung diseases | 阿德维塔生命科学有限责任公司 | 2022-09-16 | — | — | CN | disclosed |